{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:42:57Z","timestamp":1696326177591},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Atypical hemolytic uremic syndrome (aHUS) is life-threatening condition particularly when complicating allograft hematopoietic stem cell transplant (HSCT). In the past, the outcome was very poor with the majority of patients reaching end-stage renal disease or dying with little or no chances of kidney transplant (KTx) due to the high risk of relapse. The availability of C5 inhibition has opened up significant therapeutic opportunities and has improved the outcome particularly if complement dysregulation (CD) is the underlying pathogenetic mechanism.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We describe a peculiar case of a girl with aHUS complicating HSCT and her subsequent successful KTx received from the same donor thus performed without immunosuppression but anti-C5 inhibition.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Soon after HSCT performed for acute lymphoblastic leukemia, the patient developed a TMA due to CD and reached end-stage renal disease. After 2 years on dialysis, the patient received a KTx from her father who was already the HSCT donor. Given the full chimerism, no immunosuppressive agent was prescribed except a short (2 days) course of steroids and eculizumab to prevent aHUS relapse. Nine months after the KTx, the patient is well with normal renal function, no immunosuppression and continues eculizumab prevention of aHUS (1 infusion every 21 days).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>All patients with transplant-associated thrombotic microangiopathy should be screened for the causes of CD. C5 inhibition with eculizumab is an important therapeutic resource to manage this complication. When KTx is necessary, immunosuppression can be safely withhold in case of same donor for both grafts and documented full chimerism.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000002505","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T22:58:14Z","timestamp":1540594694000},"page":"e48-e51","source":"Crossref","is-referenced-by-count":1,"title":["Haploidentical Hematopoietic Stem Cell Transplant Complicated by Atypical Hemolytic Uremic Syndrome and Kidney Transplant From the Same Donor With No Immunosuppression but C5 Inhibition"],"prefix":"10.1097","volume":"103","author":[{"given":"Gianluigi","family":"Ardissino","sequence":"first","affiliation":[{"name":"Center for HUS Prevention, Control and Management at the Pediatric Nephrology, Dialysis and Transplantation Unit, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore Policlinico, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donata","family":"Cresseri","sequence":"additional","affiliation":[{"name":"Center for HUS Prevention, Control and Management at the Nephrology, Dialysis and Kidney Transplantation Unit, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore Policlinico, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Giglio","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, IRCCS S. Raffaele Scientific Institution, Milan. Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[{"name":"Oncology and Hemato-Oncology Department, University of Milan, BTM Center, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore Policlinico, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Iannuzzella","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, IRCSS Arcispedale S. Maria Nuova, Reggio Emilia, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Tel","sequence":"additional","affiliation":[{"name":"Center for HUS Prevention, Control and Management at the Pediatric Nephrology, Dialysis and Transplantation Unit, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore Policlinico, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antenore","family":"Giussani","sequence":"additional","affiliation":[{"name":"Center for HUS Prevention, Control and Management at the Kidney Transplant Unit, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore Policlinico, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piergiorgio","family":"Messa","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Cliniche e di Comunit\u00e0, Universit\u00e0 degli Studi di Milano, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selena","family":"Longhi","sequence":"additional","affiliation":[{"name":"Center for HUS Prevention, Control and Management at the Pediatric Nephrology, Dialysis and Transplantation Unit, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore Policlinico, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Vincenti","sequence":"additional","affiliation":[{"name":"UOC Coordinamento Trapianto (NITp), Dip. Servizi e Medicina Preventiva, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore Policlinico, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"Center for HUS Prevention, Control and Management at the Laboratory of Medical Genetics, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore Policlinico, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Cugno","sequence":"additional","affiliation":[{"name":"Center for HUS Prevention, Control and Management at the Internal Medicine, University of Milan, Fondazione IRCCS Ca\u2019 Granda, Ospedale Maggiore Policlinico, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, IRCCS S. Raffaele Scientific Institution, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20231002","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","year":"2012","journal-title":"Am J Transplant"},{"key":"bib2-20231002","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional test for monitoring Eculizumab treatment in patients with atypical haemolytic uremic syndrome","volume":"12","year":"2014","journal-title":"J Thromb Haemost"},{"key":"bib3-20231002","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/jth.12764","article-title":"Tailored eculizumab regimen for patients with atipical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment","volume":"13","year":"2015","journal-title":"J Thromb Haemost"},{"key":"bib4-20231002","first-page":"237","article-title":"Sensitive, reliable and easy-performed laboratory monitoring of Eculizumab therapy in atypical hemolytic uremic syndrome","volume":"170","year":"2015","journal-title":"Clin Immun"},{"key":"bib5-20231002","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/ki.2013.494","article-title":"Death from cancer: a sobering truth for patients with kidney transplant","volume":"85","year":"2014","journal-title":"Kidney Int"},{"key":"bib6-20231002","first-page":"602","article-title":"Calcineurin inhibitor nephrotoxicity: a review and perspective of evidence","volume":"17","year":"2013","journal-title":"Am J Nephrol"},{"key":"bib7-20231002","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/tri.12536","article-title":"Epidemiology of infections in kidney transplant recipients\u2014data miner's approach","volume":"28","year":"2015","journal-title":"Transpl Int"},{"key":"bib8-20231002","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00277-017-2936-7","article-title":"Haploidentical hematopoietic bone marrow transplantation followed by living kidney transplantation from the same donor in a sickle cell disease patient with end-stage renal failure","volume":"96","year":"2017","journal-title":"Ann Hematol"},{"key":"bib9-20231002","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1600-6143.2010.03352.x","article-title":"Kidney transplant from the same donor without maintenance immunosuppression after previous hematopoietic stem cell transplant","volume":"11","year":"2011","journal-title":"Am J Transplant"},{"key":"bib10-20231002","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1034\/j.1600-6143.2003.00015.x","article-title":"Outcomes of renal transplantation following bone marrow transplantation","volume":"3","year":"2003","journal-title":"Am J Transplant"},{"key":"bib11-20231002","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1097\/TP.0000000000001213","article-title":"Kidney transplantation with corticosteroids alone after haploidentical HSCT from the same donor","volume":"100","year":"2016","journal-title":"Transplantation"},{"key":"bib12-20231002","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.it.2017.07.008","article-title":"Mechanisms of mixed chimerism-based transplant tolerance","volume":"38","year":"2017","journal-title":"Trends Immunol"},{"key":"bib13-20231002","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.humimm.2017.11.008","article-title":"Preclinical and clinical studies for transplant tolerance via the mixed clinical approach","volume":"79","year":"2018","journal-title":"Hum Immunol"},{"key":"bib14-20231002","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","year":"2014","journal-title":"Blood"},{"key":"bib15-20231002","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00467-012-2283-9","article-title":"Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation","volume":"27","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"bib16-20231002","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"European working party on complement genetics in renal diseases. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"bib17-20231002","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0034-1375296","article-title":"Genetics of atypical hemolytic uremic syndrome (aHUS)","volume":"40","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"bib18-20231002","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib19-20231002","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.bmt.1704748","article-title":"Correction of recurrent angioedema related to C1 esterase inhibitor deficiency as a secondary event following nonmyeloablative allogeneic stem cell transplantation in a patient with myelofibrosis","volume":"35","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"bib20-20231002","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference","volume":"91","year":"2017","journal-title":"Kidney Int"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007890-201902000-00035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:04:06Z","timestamp":1696223046000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201902000-00035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002505","relation":{},"ISSN":["1534-6080","0041-1337"],"issn-type":[{"value":"1534-6080","type":"electronic"},{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}